Investor profile
Abingworth LLP has backed 5 European tech companies across 6 funding rounds between 2013 and 2021, joining rounds totalling €244M. Most active in Healthtech. Data as of 6 Aug 2026.
Also recorded as: Abingworth
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| GenSight Biologics | France | 2 | €64M |
| CRISPR Therapeutics | Switzerland | 1 | €59M |
| Anjarium Biosciences | Switzerland | 1 | €51M |
| Nouscom | Switzerland | 1 | €42M |
| Kesios Therapeutics |
| Company | Stage | Amount | Date |
|---|---|---|---|
| CRISPR Therapeutics | Series B | €59M | 2015-04 |
| Anjarium Biosciences | Series A | €51M | 2021-09 |
| Nouscom | Series B | €42M | 2017-11 |
| GenSight Biologics |
| UK |
| 1 |
| €27M |
| Series B |
| €32M |
| 2015-07 |
| GenSight Biologics | Series A | €32M | 2013-04 |
| Kesios Therapeutics | Series A | €27M | 2015-12 |
